(Q26825438)

language of work or name

1 reference

2014

1 reference

Human Vaccines & Immunotherapeutics

6 December 2013

12 references

23 March 2019

25 June 2019

19 September 2019

27 September 2019

3 November 2019

27 November 2019

13 December 2019

28 April 2020

1 July 2020

31 August 2020

14 July 2021

23 October 2022

13 references

23 March 2019

25 June 2019

19 September 2019

27 September 2019

3 November 2019

27 November 2019

13 December 2019

28 April 2020

1 July 2020

31 August 2020

14 July 2021

23 October 2022

10

1 reference

issue

3

1 reference

page(s)

607-14

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

copyright license

12 references

23 March 2019

25 June 2019

19 September 2019

27 September 2019

3 November 2019

27 November 2019

13 December 2019

28 April 2020

1 July 2020

31 August 2020

14 July 2021

on focus list of Wikimedia project

23 October 2022

ScienceSource

0 references

cites work

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4130285

7 April 2017

https://api.crossref.org/works/10.4161/HV.27426

Association of RSV-related hospitalization and non-compliance with palivizumab among commercially insured infants: a retrospective claims analysis

22 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4130285

Respiratory function in healthy late preterm infants delivered at 33-36 weeks of gestation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4130285

The evolution of risk factors for respiratory syncytial virus-related hospitalisation in infants born at 32-35 weeks' gestational age: time-based analysis using data from the FLIP-2 study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4130285

Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4130285

Animal models of human respiratory syncytial virus disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4130285

Respiratory morbidity and lung function in preterm infants of 32 to 36 weeks' gestational age.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4130285

Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4130285

Growth rate of lung function in healthy preterm infants.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4130285

Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4130285

The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4130285

Human IgG subclass measurements in the clinical laboratory.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4130285

Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4130285

Preterm neonates show marked leukopenia and lymphopenia that are associated with increased regulatory T-cell values and diminished IL-7.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4130285

From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4130285

Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4130285

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4130285

Bovine parainfluenza virus type 3 (PIV3) expressing the respiratory syncytial virus (RSV) attachment and fusion proteins protects hamsters from challenge with human PIV3 and RSV.

31 May 2018

1 reference

Immunization of preterm and low birth weight infants. American Academy of Pediatrics Committee on Infectious Diseases

21 January 2018

1 reference

A new direction in understanding the pathogenesis of respiratory syncytial virus bronchiolitis: how real infants suffer

21 January 2018

1 reference

Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses

21 January 2018

1 reference

Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group

21 January 2018

1 reference

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

21 January 2018

1 reference

Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry

21 January 2018

1 reference

Effects of high PCO2 on ventilated preterm lamb lungs

21 January 2018

1 reference

Trends in chronologic age and infant respiratory syncytial virus hospitalization: an 8-year cohort study

21 January 2018

1 reference

Respiratory syncytial virus hospitalizations among American Indian and Alaska Native infants and the general United States infant population

21 January 2018

1 reference

Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases

21 January 2018

1 reference

Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006.

21 January 2018

1 reference

Hospitalization for respiratory syncytial virus in the paediatric population in Spain

21 January 2018

1 reference

Rates of hospitalization for respiratory syncytial virus infection among children in medicaid

21 January 2018

1 reference

Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons

21 January 2018

1 reference

Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain

21 January 2018

1 reference

FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks

21 January 2018

1 reference

Identifying risk factors for severe respiratory syncytial virus among infants born after 33 through 35 completed weeks of gestation: different methodologies yield consistent findings

21 January 2018

1 reference

Respiratory syncytial virus--United States, July 2007-June 2011.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4130285

Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group

28 November 2018

1 reference

12 December 2020

Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group

1 reference

12 December 2020

Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis

1 reference

12 December 2020

Serum-gamma-G-globulin levels in normal premature, post-mature, and "small-for-dates" newborn babies

1 reference

12 December 2020

Identifiers

0 references

1 reference

PubMed publication ID

24316863

1 reference